ZJYL
Jin Medical·NASDAQ
--
--(--)
--
--(--)
ZJYL fundamentals
During FY 2025, Jin Medical (ZJYL) reported revenue of 20.69M, a YoY change of -11.98%. Net income was 1.38M, a YoY change of -59.61%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
FY,2018 | H1,2019 | FY,2019 | H1,2020 | FY,2020 | H1,2021 | FY,2021 | H1,2022 | FY,2022 | H1,2023 | FY,2023 | H1,2024 | FY,2024 | H1,2025 | FY,2025 | TTM |
|---|
Start Date | Oct 1, 2017 | Oct 1, 2018 | Oct 1, 2018 | Oct 1, 2019 | Oct 1, 2019 | Oct 1, 2020 | Oct 1, 2020 | Oct 1, 2021 | Oct 1, 2021 | Oct 1, 2022 | Oct 1, 2022 | Oct 1, 2023 | Oct 1, 2023 | Oct 1, 2024 | Oct 1, 2024 | -- |
End Date | Sep 30, 2018 | Mar 31, 2019 | Sep 30, 2019 | Mar 31, 2020 | Sep 30, 2020 | Mar 31, 2021 | Sep 30, 2021 | Mar 31, 2022 | Sep 30, 2022 | Mar 31, 2023 | Sep 30, 2023 | Mar 31, 2024 | Sep 30, 2024 | Mar 31, 2025 | Sep 30, 2025 | -- |
Fiscal Year-End | Sep 30 | Sep 30 | Sep 30 | Sep 30 | Sep 30 | Sep 30 | Sep 30 | Sep 30 | Sep 30 | Sep 30 | Sep 30 | Sep 30 | Sep 30 | Sep 30 | Sep 30 | -- |
Revenue | 20.91M -- | 10.18M -- | 20.37M -2.61% | 7.17M -29.59% | 16.19M -20.49% | 9.42M +31.33% | 20.76M +28.22% | 9.47M +0.55% | 19.19M -7.58% | 10.25M +8.30% | 19.82M +3.29% | 10.56M +2.96% | 23.50M +18.57% | 9.88M -6.40% | 20.69M -11.98% | 20.69M -- |
Sales and Services Revenue | 20.91M -- | 10.18M -- | 20.37M -2.61% | 7.17M -29.59% | 16.19M -20.49% | 9.42M +31.33% | 20.76M +28.22% | 9.47M +0.55% | 19.19M -7.58% | 10.25M +8.30% | 19.82M +3.29% | 10.56M +2.96% | 23.50M +18.57% | 9.88M -6.40% | 20.69M -11.98% | 20.69M -- |
Cost of Revenue | 13.25M -- | 6.31M -- | 12.86M -3.01% | 4.58M -27.55% | 10.70M -16.80% | 5.81M +26.94% | 14.40M +34.66% | 6.34M +9.08% | 12.99M -9.80% | 6.72M +6.11% | 13.04M +0.34% | 6.82M +1.46% | 14.00M +7.38% | 7.48M +9.65% | 14.64M +4.60% | 14.64M -- |
Cost of Goods and Services | 13.25M -- | -- -- | 12.86M -3.01% | -- -- | 10.70M -16.80% | -- -- | 14.40M +34.66% | -- -- | 12.99M -9.80% | -- -- | 13.04M +0.34% | 6.82M -- | 14.00M +7.38% | 7.48M +9.65% | 14.64M +4.60% | 14.64M -- |
Gross Profit | 7.66M -- | 3.87M -- | 7.51M -1.91% | 2.59M -32.92% | 5.50M -26.80% | 3.61M +39.08% | 6.36M +15.69% | 3.13M -13.19% | 6.20M -2.56% | 3.53M +12.72% | 6.78M +9.46% | 3.74M +5.82% | 9.50M +40.06% | 2.40M -35.70% | 6.04M -36.39% | 6.04M -- |
Operating Expenses | 3.43M -- | 1.60M -- | 3.11M -9.41% | 1.42M -10.93% | 3.14M +1.15% | 1.77M +24.23% | 3.73M +18.64% | 2.12M +19.84% | 4.07M +9.07% | 1.76M -16.85% | 3.92M -3.70% | 2.51M +42.50% | 5.86M +49.69% | 2.86M +13.95% | 5.44M -7.29% | 5.44M -- |
Selling, General and Administrative Expenses | 2.23M -- | 898.81K -- | 1.98M -11.24% | 910.44K +1.29% | 1.88M -4.85% | 1.19M +30.89% | 2.16M +14.91% | 1.22M +2.67% | 2.18M +0.59% | 1.13M -7.77% | 2.37M +9.16% | 1.90M +68.16% | 4.37M +83.89% | 2.20M +15.73% | 3.88M -11.18% | 3.88M -- |
Selling and Marketing Expenses | 513.10K -- | -- -- | 381.11K -25.72% | -- -- | 385.09K +1.04% | -- -- | 489.00K +26.98% | -- -- | 402.01K -17.79% | -- -- | 453.31K +12.76% | 358.77K -- | 1.10M +143.75% | 747.26K +108.28% | 1.35M +21.74% | 1.35M -- |
General and Administrative Expenses | 1.72M -- | -- -- | 1.60M -6.91% | -- -- | 1.50M -6.26% | -- -- | 1.67M +11.81% | -- -- | 1.77M +5.95% | -- -- | 1.92M +8.34% | 1.54M -- | 3.26M +69.76% | 1.45M -5.86% | 2.53M -22.33% | 2.53M -- |
Research and Development Expenses | 1.20M -- | 696.94K -- | 1.13M -6.01% | 510.86K -26.70% | 1.26M +11.66% | 574.05K +12.37% | 1.57M +24.21% | 892.52K +55.48% | 1.89M +20.79% | 631.03K -29.30% | 1.54M -18.47% | 609.64K -3.39% | 1.50M -2.95% | 660.89K +8.41% | 1.56M +4.03% | 1.56M -- |
Operating Income | 4.23M -- | 2.27M -- | 4.40M +4.17% | 1.17M -48.36% | 2.35M -46.53% | 1.84M +57.06% | 2.63M +11.76% | 1.02M -44.84% | 2.13M -19.04% | 1.77M +74.26% | 2.87M +34.58% | 1.23M -30.61% | 3.64M +26.91% | -454.21K -136.95% | 608.18K -83.29% | 608.18K -- |
Non-Operating Income (Loss) | 71.02K -- | -57.49K -- | -276.61K -489.46% | 47.38K +182.40% | -1.52K +99.45% | 255.16K +438.60% | 248.84K +16460.62% | 259.73K +1.79% | 612.11K +145.98% | 198.94K -23.40% | 354.68K -42.06% | 784.17K +294.17% | 544.97K +53.65% | 482.78K -38.43% | 987.63K +81.23% | 987.63K -- |
Gain (Loss) on Foreign Currency Exchange | 186.93K -- | -- -- | -330.21K -276.65% | -- -- | -12.39K +96.25% | -- -- | 63.35K +611.26% | -- -- | 186.39K +194.21% | -- -- | -50.41K -127.04% | 414 -- | -26.77K +46.88% | 58.86K +14116.67% | 23.07K +186.17% | 23.07K -- |
Other Non-Operating Income (Loss) | -90.66K -- | -23.21K -- | 76.45K +184.33% | 101.88K +538.95% | 123.28K +61.25% | 289.44K +184.10% | 194.98K +58.17% | 189.94K -34.38% | 244.12K +25.20% | 104.37K -45.05% | 222.40K -8.90% | 102.16K -2.12% | 105.22K -52.69% | 122.38K +19.79% | 175.49K +66.79% | 175.49K -- |
Net Interest Expense | 25.24K -- | 34.28K -- | 22.85K -9.50% | 54.51K +58.98% | 112.40K +392.01% | 34.27K -37.12% | 9.49K -91.56% | -69.80K -303.63% | -181.60K -2013.24% | -94.57K -35.50% | -182.68K -0.59% | -681.59K -620.72% | -466.52K -155.37% | -301.54K +55.76% | -789.07K -69.14% | -789.07K -- |
Interest Expense | 25.24K -- | -- -- | 22.85K -9.50% | -- -- | 112.40K +392.01% | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Interest Income | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 69.80K -- | 181.60K -- | 94.57K +35.50% | 182.68K +0.59% | 681.59K +620.72% | 466.52K +155.37% | 301.54K -55.76% | 789.07K +69.14% | 789.07K -- |
Pretax Income From Continuing Operations | 4.30M -- | 2.21M -- | 4.13M -3.99% | 1.22M -44.88% | 2.35M -42.98% | 2.10M +71.87% | 2.88M +22.40% | 1.28M -39.17% | 2.74M -4.78% | 1.97M +54.39% | 3.22M +17.48% | 2.01M +2.18% | 4.18M +29.85% | 28.56K -98.58% | 1.60M -61.86% | 1.60M -- |
Income Tax Expense | 616.88K -- | 161.83K -- | 479.63K -22.25% | 49.67K -69.31% | 147.15K -69.32% | 256.94K +417.30% | 248.64K +68.97% | 50.41K -80.38% | 36.11K -85.48% | 204.05K +304.80% | 343.71K +851.81% | 309.01K +51.44% | 763.88K +122.25% | 19.57K -93.67% | 214.57K -71.91% | 214.57K -- |
Current Income Tax | 629.83K -- | -- -- | 509.99K -19.03% | -- -- | 307.78K -39.65% | -- -- | 250.31K -18.67% | -- -- | 122.13K -51.21% | -- -- | 254.10K +108.05% | 285.30K -- | 727.55K +186.32% | 36.84K -87.09% | 236.64K -67.47% | 236.64K -- |
Deferred Income Tax | -12.95K -- | -- -- | -30.36K -134.43% | -- -- | -160.62K -429.13% | -- -- | -1.66K +98.96% | -- -- | -86.02K -5069.65% | -- -- | 89.60K +204.16% | 23.71K -- | 36.33K -59.46% | -17.27K -172.84% | -22.07K -160.74% | -22.07K -- |
Net Income | 3.68M -- | 2.05M -- | 3.65M -0.93% | 1.17M -42.95% | 2.21M -39.52% | 1.84M +57.21% | 2.63M +19.30% | 1.23M -33.41% | 2.71M +2.84% | 1.77M +44.09% | 2.88M +6.34% | 1.70M -3.51% | 3.42M +18.82% | 9.00K -99.47% | 1.38M -59.61% | 1.38M -- |
Net Income Attributable to Minority Interests | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | 0 -- | -89.70K -- | -256.09K -- | 98.01K +209.25% | 189.95K +174.17% | 189.95K -- |
Net Income Attributable to Owners of the Company | 3.68M -- | 2.05M -- | 3.65M -0.93% | 1.17M -42.95% | 2.21M -39.52% | 1.84M +57.21% | 2.63M +19.30% | 1.23M -33.41% | 2.71M +2.84% | 1.77M +44.09% | 2.88M +6.34% | 1.79M +1.57% | 3.68M +27.71% | -89.01K -104.96% | 1.19M -67.59% | 1.19M -- |
Net Income Attributable to Common Stockholders | 3.68M -- | 2.05M -- | 3.65M -0.93% | 1.17M -42.95% | 2.21M -39.52% | 1.84M +57.21% | 2.63M +19.30% | 1.23M -33.41% | 2.71M +2.84% | 1.77M +44.09% | 2.88M +6.34% | 1.79M +1.57% | 3.68M +27.71% | -89.01K -104.96% | 1.19M -67.59% | 1.19M -- |
Other Comprehensive Income | -326.08K -- | 246.54K -- | -418.24K -28.26% | 60.75K -75.36% | -49.32K +88.21% | 403.92K +564.86% | 594.72K +1305.73% | 268.28K -33.58% | -1.50M -352.17% | 570.16K +112.52% | -493.23K +67.11% | 159.42K -72.04% | 841.52K +270.61% | -805.14K -605.03% | -361.24K -142.93% | -361.24K -- |
Total Comprehensive Income | 3.36M -- | 2.30M -- | 3.23M -3.76% | 1.23M -46.42% | 2.16M -33.21% | 2.24M +82.25% | 3.23M +49.60% | 1.49M -33.44% | 1.21M -62.60% | 2.34M +56.38% | 2.38M +97.63% | 1.86M -20.23% | 4.26M +78.67% | -796.14K -142.72% | 1.02M -76.06% | 1.02M -- |
Total Comprehensive Income Attributable to Minority Interests | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | 0 -- | -89.25K -- | -262.72K -- | 106.50K +219.32% | 196.47K +174.78% | 196.47K -- |
Total Comprehensive Income Attributable to Owners of the Company | 3.36M -- | 2.30M -- | 3.23M -3.76% | 1.23M -46.42% | 2.16M -33.21% | 2.24M +82.25% | 3.23M +49.60% | 1.49M -33.44% | 1.21M -62.60% | 2.34M +56.38% | 2.38M +97.63% | 1.95M -16.41% | 4.52M +89.69% | -902.63K -146.22% | 823.54K -81.80% | 823.54K -- |
Basic EPS | 0.18 -- | 0.1 -- | 0.18 -- | 0.06 -40.00% | 0.33 +83.33% | 0.27 +350.00% | 0.02 -93.94% | 0.18 -33.33% | 0.02 -- | 0.01 -94.44% | 0.02 -- | 0.01 -- | 0.02 -- | 0 -100.00% | 0.01 -50.00% | 0.01 -- |
Basic EPS from Continuing Operations | 0.18 -- | -- -- | 0.18 -- | -- -- | 0.33 +83.33% | -- -- | 0.02 -93.94% | -- -- | 0.02 -- | -- -- | 0.02 -- | 0.01 -- | 0.02 -- | 0 -100.00% | 0.01 -50.00% | 0.01 -- |
Diluted EPS | 0.18 -- | 0.1 -- | 0.18 -- | 0.06 -40.00% | 0.33 +83.33% | 0.27 +350.00% | 0.02 -93.94% | 0.18 -33.33% | 0.02 -- | 0.01 -94.44% | 0.02 -- | 0.01 -- | 0.02 -- | 0 -100.00% | 0.01 -50.00% | 0.01 -- |
Diluted EPS from Continuing Operations | 0.18 -- | -- -- | 0.18 -- | -- -- | 0.33 +83.33% | -- -- | 0.02 -93.94% | -- -- | 0.02 -- | -- -- | 0.02 -- | 0.01 -- | 0.02 -- | 0 -100.00% | 0.01 -50.00% | 0.01 -- |
You can ask Aime
What guidance did Jin Medical's management provide for the next earnings period?What factors drove the changes in Jin Medical's revenue and profit?What were the key takeaways from Jin Medical's earnings call?What is the revenue and EPS growth rate for Jin Medical year over year?What were the key takeaways from Jin Medical’s earnings call?Did Jin Medical beat or miss consensus estimates last quarter?What is the market's earnings forecast for Jin Medical next quarter?What is Jin Medical's latest dividend and current dividend yield?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
